The European health regulator on 5 June 2014 lifted suspension imposed on export of drugs produced at the Ranbaxy’s Toansa plant in Punjab in India. The imposed ban was lifted by terming that the medicines produced at the site don’t pose any threat to public health despite having number of manufacturing deficiencies.
The European Medicines Agency (EMA) announced that assessment of reported non-compliance with Good Manufacturing Practice (GMP) at Ranbaxy Laboratories at Toansa, India has been finalised by the European regulatory authorities. The assessment showed a number of GMP deficiencies at the concerned site, but doesn’t pose any threat to public health.
Based on the assessment report of the regulatory authorities, the GMP certificate of the plant will be reinstated which was suspended in January 2014 in European Union. The certificate will be re-entered into EudraGMDP, the EU database that contains GMP certificates.
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.